13F Holdings
中文EN

MRK Merck & Co., Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 310158 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.9%
TTM net income YoY-87.1%
TTM EPS YoY-86.9%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR-19.0%

Margins

Gross margin71.8%
Operating margin—
Net margin3.6%
FCF margin21.9%
EBITDA margin—

Returns

ROE5.1%
ROA1.9%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets66.1%
Debt / equity1.20x
Current ratio1.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income7.62x
Accruals ratio-12.4%
Payout ratio341.1%
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$65.01B$64.17B$60.12B$59.28B$48.70B
Cost of revenue$16.38B$15.19B$16.13B$17.41B$13.63B
Gross profit$48.63B$48.98B$43.99B$41.87B$35.08B
R&D expense$15.79B$17.94B$30.53B$13.55B$12.24B
SG&A expense$10.73B$10.82B$10.50B$10.04B$9.63B
Interest expense$1.36B$1.27B$1.15B$962.00M$806.00M
Pretax income$21.07B$19.94B$1.89B$16.44B$13.88B
Income tax$2.80B$2.80B$1.51B$1.92B$1.52B
Net income$18.25B$17.12B$365.00M$14.52B$13.05B
EPS (basic)7.306.760.145.735.16
EPS (diluted)7.286.740.145.715.14
Dividends declared per share3.283.122.962.802.64
Weighted avg. shares (diluted)2.51B2.54B2.55B2.54B2.54B
Balance sheet
Cash & equivalents$14.56B$13.32B$6.91B$12.77B$8.17B
Short-term investments$0$447.00M$252.00M$498.00M$0
Receivables$11.78B$10.28B$10.35B$9.45B$9.23B
Inventory$6.66B$6.11B$6.36B$5.91B$5.95B
Current assets$43.52B$38.78B$32.17B$35.72B$30.27B
PP&E, net$25.32B$23.78B$23.05B$21.42B$19.28B
Goodwill$21.58B$21.67B$21.20B$21.20B$21.26B
Intangibles$26.68B$16.37B$18.01B$20.27B$22.93B
Total assets$136.87B$117.11B$106.67B$109.16B$105.69B
Current liabilities$28.33B$28.42B$25.69B$24.24B$23.87B
Short-term debt$2.59B$2.65B$1.37B$1.95B$2.41B
Long-term debt$46.75B$34.46B$33.68B$28.75B$30.69B
Total debt$49.34B$37.11B$35.05B$30.69B$33.10B
Total liabilities$84.20B$70.73B$69.04B$63.10B$67.44B
Shareholders' equity$52.61B$46.31B$37.58B$45.99B$38.18B
Net debt$34.77B$23.79B$28.15B$17.92B$24.93B
Cash flow statement
Operating cash flow$16.47B$21.47B$13.01B$19.09B$13.12B
Capital expenditure$4.11B$3.37B$3.86B$4.39B$4.45B
Free cash flow$12.36B$18.10B$9.14B$14.71B$8.67B
Investing cash flow-$13.74B-$7.73B-$14.08B-$4.96B-$16.42B
Financing cash flow-$1.92B-$7.03B-$4.81B-$9.12B$3.10B
Depreciation & amortization$3.04B$2.10B$1.83B$1.82B$1.58B
Stock-based compensation$820.00M$761.00M$645.00M$541.00M$479.00M
Dividends paid$8.18B$7.84B$7.45B$7.01B$6.61B
Share buybacks$5.08B$1.31B$1.35B$0$840.00M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.